Literature DB >> 9833945

Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats.

R Vettor1, C Pagano, M Granzotto, P Englaro, P Angeli, W F Blum, G Federspil, F Rohner-Jeanrenaud, B Jeanrenaud.   

Abstract

Intracerebroventricular administration of neuropeptide Y to normal rats induces a syndrome characterised by obesity, hyperinsulinaemia, insulin resistance and over expression of the adipose tissue ob gene. Little is known about the effect of circulating neuropeptide Y on glucose metabolism, insulin secretion and leptin. We therefore aimed to evaluate the effect of an intravenous infusion of neuropeptide Y on glucose disposal, endogenous glucose production, whole body glycolytic flux, and glucose storage as assessed during euglycaemic hyperinsulinaemic clamp. In addition, the insulin-stimulated glucose utilisation index in individual tissues was measured by the 2-deoxy-[1-3H]-glucose technique. The effect of neuropeptide Y on insulin secretion was evaluated by hyperglycaemic clamp. Infusion did not induce any change in endogenous glucose production during basal conditions or at the end of the clamp. Glucose disposal was significantly increased in the rats given neuropeptide Y compared with controls (27.8 +/- 1.3 vs 24.3 +/- 1.6 mg x min(-1) x kg(-1); p < 0.05) as was the glycolytic flux (18.9 +/- 1.6 vs 14.4 +/- 0.8 mg x min(-1) x kg(-1); p < 0.05), while glucose storage was comparable in the two groups. In skeletal muscle, the glucose utilisation index was increased significantly in rats given neuropeptide Y. The glucose utilisation index in subcutaneous and epididimal adipose tissue was not significantly different between the two groups. Plasma leptin was significantly increased by hyperinsulinaemia, but was not affected by neuropeptide Y infusion. Both the early and late phase of the insulin response to hyperglycaemia were significantly reduced by neuropeptide Y. In conclusion neuropeptide Y infusion may increase insulin-induced glucose disposal in normal rats, accelerating its utilisation through the glycolytic pathway. Neuropeptide Y reduces both phases of the insulin response to hyperglycaemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833945     DOI: 10.1007/s001250051077

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  4 in total

1.  The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

Authors:  Lucy C Pickavance; Christian L Brand; Karsten Wassermann; John P H Wilding
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 2.  Pancreatic regulation of glucose homeostasis.

Authors:  Pia V Röder; Bingbing Wu; Yixian Liu; Weiping Han
Journal:  Exp Mol Med       Date:  2016-03-11       Impact factor: 8.718

3.  Berberine for Appetite Suppressant and Prevention of Obesity.

Authors:  Hyun-Jung Park; EunYee Jung; Insop Shim
Journal:  Biomed Res Int       Date:  2020-12-12       Impact factor: 3.411

4.  Neuropeptide Y in the noradrenergic neurons induces the development of cardiometabolic diseases in a transgenic mouse model.

Authors:  Suvi T Ruohonen; Ullamari Pesonen; Eriika Savontaus
Journal:  Indian J Endocrinol Metab       Date:  2012-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.